Back to results
US 2026/0159543 A1Published application
Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
AssigneeRhythm Pharmaceuticals, Inc.
InventorsLouis Anthony Tartaglia, Bart Henderson, Leonardus H.T. Van Der Ploeg
Life of this patent
Estimating the term…
Abstract
A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).
Claims10
A method of treating a disorder in a subject in need thereof, comprising:
- administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R),
- wherein the subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).
Dependencies are inferred from the claim text.